Haemonetics (HAE)
(Delayed Data from NYSE)
$91.42 USD
-0.16 (-0.17%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $91.41 -0.01 (-0.01%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth F Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
HAE 91.42 -0.16(-0.17%)
Will HAE be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for HAE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HAE
Boston Scientific (BSX) Q2 Earnings Beat, Organic Sales Rise
Thermo Fisher (TMO) Beats on Q2 Earnings, Raises 2024 EPS View
HAE: What are Zacks experts saying now?
Zacks Private Portfolio Services
AtriCure (ATRC) Gains China Approval for AtriClip LAA System
HAE vs. BSX: Which Stock Is the Better Value Option?
Cardinal Health's (CAH) China Syringe Makers Face FDA Warnings
Other News for HAE
Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2025 Results: August 8, 2024
Haemonetics Undervalued As It Passes Into A Period Of Softer Reported Growth
Haemonetics Launches Limited Market Release for New VASCADE MVP XL Vascular Closure Device
This McCormick Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday
AMD initiated, Paramount downgraded: Wall Street's top analyst calls